AIMS: To study possible selective prescribing ('channelling') we compared characteristics of patients using the SSRI sertraline with patients using longer available SSRIs. METHODS: An observational cohort study in 1251 patients being prescribed an SSRI. RESULTS: In contrast to other studies, we found no evidence for channeling of sertraline. Sertraline was mainly prescribed for the labelled indication (depressive disorder), while older SSRIs were more often prescribed also for other indications. Time on the market was inversely associated to the proportion of patients treated for depressive disorder. CONCLUSIONS: We found no evidence for channeling of sertraline compared with prescribing patterns of older SSRIs.
AIMS: To study possible selective prescribing ('channelling') we compared characteristics of patients using the SSRI sertraline with patients using longer available SSRIs. METHODS: An observational cohort study in 1251 patients being prescribed an SSRI. RESULTS: In contrast to other studies, we found no evidence for channeling of sertraline. Sertraline was mainly prescribed for the labelled indication (depressive disorder), while older SSRIs were more often prescribed also for other indications. Time on the market was inversely associated to the proportion of patients treated for depressive disorder. CONCLUSIONS: We found no evidence for channeling of sertraline compared with prescribing patterns of older SSRIs.
Authors: June Almenoff; Joseph M Tonning; A Lawrence Gould; Ana Szarfman; Manfred Hauben; Rita Ouellet-Hellstrom; Robert Ball; Ken Hornbuckle; Louisa Walsh; Chuen Yee; Susan T Sacks; Nancy Yuen; Vaishali Patadia; Michael Blum; Mike Johnston; Charles Gerrits; Harry Seifert; Karol Lacroix Journal: Drug Saf Date: 2005 Impact factor: 5.606
Authors: Richard C Clark; Simon R J Maxwell; Sheena Kerr; Melinda Cuthbert; Duncan Buchanan; Doug Steinke; David J Webb; Nicholas D Bateman Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Hyungjin Myra Kim; Kara Zivin; Dara Ganoczy; Paul Pfeiffer; Katherine Hoggatt; John F McCarthy; Karen Downing; Marcia Valenstein Journal: Pharmacoepidemiol Drug Saf Date: 2010-10 Impact factor: 2.890
Authors: Buster Mannheimer; Björn Wettermark; Michael Lundberg; Hans Pettersson; Christer von Bahr; Erik Eliasson Journal: Br J Clin Pharmacol Date: 2010-04 Impact factor: 4.335